{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:34:00Z","timestamp":1784266440339,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1124\/jpet.114.214304","type":"journal-article","created":{"date-parts":[[2014,5,21]],"date-time":"2014-05-21T23:31:15Z","timestamp":1400715075000},"page":"232-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Effect of LX4211 on Glucose Homeostasis and Body Composition in Preclinical Models"],"prefix":"10.1016","volume":"350","author":[{"given":"David R.","family":"Powell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"DaCosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deon","family":"Doree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Buhring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Heydorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Nouraldeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmaja","family":"Yalamanchili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faika","family":"Mseeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Shadoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Zambrowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ming","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.114.214304_bib1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s11892-012-0275-6","article-title":"Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus","volume":"12","author":"Abdul-Ghani","year":"2012","journal-title":"Curr Diab Rep"},{"issue":"Suppl 1","key":"10.1124\/jpet.114.214304_bib2","first-page":"S11","article-title":"Standards of medical care in diabetes\u20142013","volume":"36","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.114.214304_bib3","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2337\/dc11-0291","article-title":"Effects of exenatide on measures of \u03b2-cell function after 3 years in metformin-treated patients with type 2 diabetes","volume":"34","author":"Bunck","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.114.214304_bib4","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.2337\/dc11-2289","article-title":"Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity","volume":"35","author":"Cohen","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.114.214304_bib5","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"Defronzo","year":"2009","journal-title":"Diabetes"},{"key":"10.1124\/jpet.114.214304_bib6","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/oby.2012.59","article-title":"Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats","volume":"20","author":"Devenny","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"10.1124\/jpet.114.214304_bib7","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1021\/jm900951n","article-title":"Novel l-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes","volume":"52","author":"Goodwin","year":"2009","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.114.214304_bib8","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.2337\/dc09-0459","article-title":"Projecting the future diabetes population size and related costs for the U.S","volume":"32","author":"Huang","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.114.214304_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1507\/endocrj1954.17.23","article-title":"General survey of diabetic features of yellow KK mice","volume":"17","author":"Iwatsuka","year":"1970","journal-title":"Endocrinol Jpn"},{"key":"10.1124\/jpet.114.214304_bib10","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2337\/db10-1328","article-title":"SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function","volume":"60","author":"Jurczak","year":"2011","journal-title":"Diabetes"},{"key":"10.1124\/jpet.114.214304_bib11","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/db10-1392","article-title":"Effects of rosiglitazone, glyburide, and metformin on \u03b2-cell function and insulin sensitivity in ADOPT","volume":"60","author":"Kahn","year":"2011","journal-title":"Diabetes"},{"key":"10.1124\/jpet.114.214304_bib12","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.2337\/dc12-1596","article-title":"Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment","volume":"36","author":"Kashyap","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.114.214304_bib13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejphar.2009.07.001","article-title":"Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice","volume":"618","author":"Katsuno","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.114.214304_bib14","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1007\/s00125-011-2204-7","article-title":"Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol","volume":"54","author":"Lim","year":"2011","journal-title":"Diabetologia"},{"key":"10.1124\/jpet.114.214304_bib15","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/j.1463-1326.2010.01291.x","article-title":"The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats","volume":"12","author":"Macdonald","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.114.214304_bib16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/07853890.2011.560181","article-title":"A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials","volume":"44","author":"Musso","year":"2012","journal-title":"Ann Med"},{"key":"10.1124\/jpet.114.214304_bib17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1124\/jpet.114.214304_bib18","first-page":"51S","article-title":"Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults\u2014the evidence report","volume":"6","year":"1998","journal-title":"Obes Res"},{"key":"10.1124\/jpet.114.214304_bib19","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.2337\/diabetes.48.9.1794","article-title":"T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes","volume":"48","author":"Oku","year":"1999","journal-title":"Diabetes"},{"key":"10.1124\/jpet.114.214304_bib20","doi-asserted-by":"crossref","first-page":"E117","DOI":"10.1152\/ajpendo.00439.2012","article-title":"Improved glycemic control in mice lacking Sglt1 and Sglt2","volume":"304","author":"Powell","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1124\/jpet.114.214304_bib21","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1124\/jpet.113.203364","article-title":"LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium\/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose","volume":"345","author":"Powell","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.214304_bib22","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2010-3011","article-title":"Cardiovascular disease in diabetes: where does glucose fit in?","volume":"96","author":"Reusch","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/jpet.114.214304_bib23","first-page":"2780","article-title":"Impact of LX4211, a dual inhibitor of sodium glucose transporter 1 and 2, on cardiovascular risk factors in type 2 diabetes (Abstract)","volume":"126","author":"Rosenstock","year":"2012","journal-title":"Circulation"},{"key":"10.1124\/jpet.114.214304_bib24","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1172\/JCI113157","article-title":"Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats","volume":"80","author":"Rossetti","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.114.214304_bib25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/10.1210\/er.2006-0038","article-title":"\u03b2-cell failure in diabetes and preservation by clinical treatment","volume":"28","author":"Wajchenberg","year":"2007","journal-title":"Endocr Rev"},{"key":"10.1124\/jpet.114.214304_bib26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/clpt.2012.58","article-title":"LX4211, a dual SGLT1\/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial","volume":"92","author":"Zambrowicz","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.114.214304_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.clinthera.2013.01.010","article-title":"Effects of LX4211, a dual SGLT1\/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes","volume":"35","author":"Zambrowicz","year":"2013","journal-title":"Clin Ther"},{"key":"10.1124\/jpet.114.214304_bib28","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.clinthera.2013.06.011","article-title":"Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects","volume":"35","author":"Zambrowicz","year":"2013","journal-title":"Clin Ther"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524187496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524187496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.114.214304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T12:43:38Z","timestamp":1739969018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524187496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0022356524187496"],"URL":"https:\/\/doi.org\/10.1124\/jpet.114.214304","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718409245.793498389","asserted-by":"object"}]},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of LX4211 on Glucose Homeostasis and Body Composition in Preclinical Models","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.114.214304","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}